A Comprehensive Review of Novel Drug-Disease Models in Diabetes Drug Development

Clinical Pharmacokinetics
Puneet GaitondeStephan Schmidt

Abstract

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease, which affects millions of people worldwide. The disease is characterized by chronically elevated blood glucose concentrations (hyperglycaemia), which result in comorbidities and multi-organ dysfunction. This is due to a gradual loss of glycaemic control as a result of increasing insulin resistance, as well as decreasing β-cell function. The objective of T2DM drug interventions is, therefore, to reduce fasting and postprandial blood glucose concentrations to normal, healthy levels without hypoglycaemia. Several classes of novel antihyperglycaemic drugs with various mechanisms of action have been developed over the past decades or are currently under clinical development. The development of these drugs is routinely supported by the application of pharmacokinetic/pharmacodynamic modelling and simulation approaches. They integrate information on the drug's pharmacokinetics, clinically relevant biomarker information and disease progression into a single, unifying approach, which can be used to inform clinical study design, dose selection and drug labelling. The objective of this review is to provide a comprehensive overview of the quantitative approaches that have been ...Continue Reading

References

Mar 1, 1984·The Journal of Clinical Endocrinology and Metabolism·W K WardD Porte
Aug 31, 1995·The New England Journal of Medicine·M StumvollJ E Gerich
May 10, 2002·Journal of Pharmacokinetics and Pharmacodynamics·D E Mager, W J Jusko
Sep 25, 2003·Journal of Cellular Biochemistry·Lubing ZhouKeith T Demarest
Oct 28, 2003·Diabetes Care·David M Eddy, Leonard Schlessinger
Aug 5, 2004·The Journal of Clinical Endocrinology and Metabolism·Amalia GastaldelliRalph A DeFronzo
Sep 1, 2005·Pharmaceutical Research·Meindert DanhofGilles Paintaud
Nov 12, 2005·Journal of Pharmacokinetics and Pharmacodynamics·Raymond MillerRichard L Lalonde
Oct 28, 2006·Annual Review of Pharmacology and Toxicology·Meindert DanhofRob A Voskuyl
Oct 2, 2007·Journal of Clinical Pharmacology·Petra M JauslinMats O Karlsson
May 20, 2008·Expert Opinion on Drug Metabolism & Toxicology·Michael A PacanowskiChristina L Aquilante
Jun 20, 2008·Clinical Pharmacokinetics·Cornelia B Landersdorfer, William J Jusko
Sep 25, 2008·The Journal of Clinical Endocrinology and Metabolism·Jessica E MatthewsUNKNOWN Albiglutide Study Group
Dec 31, 2008·Diabetes Care·James F ListFred T Fiedorek
Sep 23, 2009·The Journal of Endocrinology·Yi Lin, Zhongjie Sun
Mar 12, 2010·Journal of Clinical Pharmacology·Petra M JauslinMats O Karlsson
Apr 27, 2010·Diabetes, Obesity & Metabolism·Vivian A FonsecaBart Staels
Feb 10, 2011·Journal of Diabetes Science and Technology·Erica J Caveney, Oren J Cohen
May 6, 2011·Diabetes Care·Franz M MatschinskyJoseph Grimsby
Feb 3, 2012·The Journal of Biological Chemistry·Shenping LiuXiayang Qiu
Feb 18, 2012·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Tessey Jose, Silvio E Inzucchi
Mar 2, 2012·The Journal of Pharmacology and Experimental Therapeutics·Wei Gao, William J Jusko
Mar 24, 2012·British Journal of Clinical Pharmacology·Cornelia B LandersdorferWilliam J Jusko

❮ Previous
Next ❯

Citations

Jul 14, 2018·Journal of Diabetes Science and Technology·Katharina FritzenOliver Schnell
Jul 31, 2021·Biopharmaceutics & Drug Disposition·Jeffry Adiwidjaja, Lucy Sasongko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Biomarkers for Diabetes

This feed focuses on the latest research on biomarkers used for monitoring disease progression in diabetes.